MORPHOSYS AG/ DE0006632003 /
2024-08-01 4:58:21 PM | Chg. -0.05 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
67.90EUR | -0.07% | 5 Turnover: 339.50 |
-Bid Size: - | -Ask Size: - | 2.54 bill.EUR | - | - |
GlobeNewswire
2021-06-03
CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire
2021-06-02
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire
2020-04-27
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire
2019-04-23
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
2019-04-23
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire
2019-01-31
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire
2018-09-13
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
2018-09-13
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire
2018-09-12
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
2018-09-12
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire
2018-07-19
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
2018-07-19
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire
2018-05-01
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
2018-05-01
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire
2018-02-17
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire
2018-02-17
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire
2017-09-27
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire
2017-09-27
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...